Wilmington Savings Fund Society FSB Cuts Holdings in Zoetis Inc. $ZTS

Wilmington Savings Fund Society FSB lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 15.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,249 shares of the company’s stock after selling 6,235 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Zoetis were worth $5,158,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ZTS. Vanguard Group Inc. raised its position in Zoetis by 0.8% during the second quarter. Vanguard Group Inc. now owns 41,886,987 shares of the company’s stock worth $6,532,276,000 after acquiring an additional 330,823 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Zoetis by 0.9% during the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock valued at $1,721,356,000 after acquiring an additional 95,294 shares during the last quarter. Norges Bank purchased a new stake in Zoetis during the 2nd quarter worth about $809,491,000. Brown Advisory Inc. raised its stake in Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after purchasing an additional 250,829 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Zoetis by 113.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after purchasing an additional 1,995,491 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the subject of several recent analyst reports. Barclays initiated coverage on shares of Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. UBS Group dropped their price target on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. KeyCorp began coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, The Goldman Sachs Group raised Zoetis to a “buy” rating in a research report on Monday, December 15th. Six research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $160.18.

Zoetis Stock Down 0.4%

Shares of NYSE:ZTS opened at $124.79 on Friday. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a 50 day moving average of $123.21 and a two-hundred day moving average of $139.62. The company has a market capitalization of $54.99 billion, a price-to-earnings ratio of 21.01, a price-to-earnings-growth ratio of 2.55 and a beta of 0.97. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.40.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The firm had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the prior year, the business posted $1.58 earnings per share. Zoetis’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.7%. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.